AbstractNarcolepsy is a chronic neurological disease characterized by diurnal excessive sleepiness and catapleaxy. It affects 1 in every 2000 to 4000 individuals with personal, social and familiar significant repercussions. The treatment of narcolepsy is mainly based on the use of stimulants for the control of the diurnal excessive sleepiness, in conjunction with behavioral measures and sleep hygiene. Among the stimulants, modafinil has presently been the drug of choice for the treatment of the diurnal excessive sleepiness in patients with narcolepsy. In the worldwide experience, its use is better tolerated and the majority of its side effects is considered light or moderate. However, the clinical use in Brazil was initiated at the end of 2...
Excessive daytime sleepiness (EDS), of very similar pattern to that seen in narcolepsy syndrome, is ...
International audienceCentral hypersomnias include narcolepsy type 1, type 2 and idiopathic hypersom...
Objective: This study assessed the efficacy and safety of armodafinil, the longer half-life enantiom...
AbstractNarcolepsy is a chronic neurological disease characterized by diurnal excessive sleepiness a...
AbstractNarcolepsy is a disease in which there is diurnal excessive sleepiness with sleep attacks an...
Objectives: To assess the efficacy and safety of modafinil for improving wakefulness in narcolepsy p...
AbstractThis is the first report describing the efficacy of modafinil therapy for narcolepsy in pati...
Narcolepsy is a neurological disorder characterized, in its classical form, by excessive daytime sle...
Objectives: To describe the pharmacological treatments (2005–2017) and the healthcare utilization (1...
Excessive daytime sleepiness (EDS), of very similar pattern to that seen in narcolepsy syndrome, is ...
International audienceNarcolepsy type 1 and narcolepsy type 2 are central disorders of hypersomnolen...
Objectives To describe the pharmacological treatments (2005-2017) and the healthcare utilization (19...
Modafinil is a novel wake-promoting agent approved by the FDA ameliorating excessive daytime sleepin...
Este artigo relata as conclusões da reunião de consenso da Associação Brasileira de Sono com médicos...
Patients with myotonic dystrophy frequently suffer from excess daytime sleepiness, which can be a si...
Excessive daytime sleepiness (EDS), of very similar pattern to that seen in narcolepsy syndrome, is ...
International audienceCentral hypersomnias include narcolepsy type 1, type 2 and idiopathic hypersom...
Objective: This study assessed the efficacy and safety of armodafinil, the longer half-life enantiom...
AbstractNarcolepsy is a chronic neurological disease characterized by diurnal excessive sleepiness a...
AbstractNarcolepsy is a disease in which there is diurnal excessive sleepiness with sleep attacks an...
Objectives: To assess the efficacy and safety of modafinil for improving wakefulness in narcolepsy p...
AbstractThis is the first report describing the efficacy of modafinil therapy for narcolepsy in pati...
Narcolepsy is a neurological disorder characterized, in its classical form, by excessive daytime sle...
Objectives: To describe the pharmacological treatments (2005–2017) and the healthcare utilization (1...
Excessive daytime sleepiness (EDS), of very similar pattern to that seen in narcolepsy syndrome, is ...
International audienceNarcolepsy type 1 and narcolepsy type 2 are central disorders of hypersomnolen...
Objectives To describe the pharmacological treatments (2005-2017) and the healthcare utilization (19...
Modafinil is a novel wake-promoting agent approved by the FDA ameliorating excessive daytime sleepin...
Este artigo relata as conclusões da reunião de consenso da Associação Brasileira de Sono com médicos...
Patients with myotonic dystrophy frequently suffer from excess daytime sleepiness, which can be a si...
Excessive daytime sleepiness (EDS), of very similar pattern to that seen in narcolepsy syndrome, is ...
International audienceCentral hypersomnias include narcolepsy type 1, type 2 and idiopathic hypersom...
Objective: This study assessed the efficacy and safety of armodafinil, the longer half-life enantiom...